Systemic angiogenic protein changes following propranolol therapy in infantile hemangioma: a multi-target perspective
Frontiers in Pharmacology · 19.12.2025 · 16
DOI: 10.3389/fphar.2025.1706048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.12.2025. Verfasst von Lijun Liang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, General Hospital of Ningxia Medical University, Yinchuan, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Infantile hemangioma (IH) is a common benign vascular tumor in infants, often requiring intervention due to potential functional impairment and cosmetic concerns. Propranolol, a nonselective β-adrenergic receptor blocker, is the first-line therapy for IH, yet its mechanisms remain incompletely elucidated.
Methods
This prospective study investigated the systemic angiogenic protein profile changes in response to propranolol in 14 treatment-naïve IH infants compared to 14 healthy controls using antibody array analysis.
Results
We identified twenty-six angiogenic proteins significantly downregulated in pretreatment IH patients compared to healthy controls. After 3 months of propranolol treatment, six proteins including HB-EGF, TGFα, ANGPTL4, Follistatin, Tie-1 and PLGF were significantly upregulated. Bioinformatic enrichment analysis revealed that these proteins are involved in key biological processes and signaling pathways, including epithelial cell proliferation, angiogenesis regulation, VEGF signaling, ERBB-EGFR axis, Ras-MAPK, and PI3K-Akt pathways.
Discussion
These results suggest that propranolol treatment is associated with a rebalancing of dysregulated angiogenic proteins in IH, through modulating both pro- and anti-angiogenic factors to rebalance vascular homeostasis. Our study provides novel insights into the systems-level pharmacological actions of propranolol and proposes potential biomarkers for treatment response evaluation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, General Hospital of Ningxia Medical University, Yinchuan, China.
- Ningxia Health Vocational and Technical College, Shizuishan, China.
- Graduate School, Dalian Medical University, Liaoning, China.
- The First Clinical Medical College of Ningxia Medical University, Yinchuan, China.
Zitieren
APA
Liang, L., Zhang, Y., Ma, Y., Liu, J., Du, W., & Ma, Q. (2025). Systemic angiogenic protein changes following propranolol therapy in infantile hemangioma: a multi-target perspective. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1706048
Vancouver
Liang L, Zhang Y, Ma Y, Liu J, Du W, Ma Q. Systemic angiogenic protein changes following propranolol therapy in infantile hemangioma: a multi-target perspective. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1706048
BibTeX
@article{Liang2025,
author = {Liang, Lijun and Zhang, Yan and Ma, Yan and Liu, Jing and Du, Wangnan and Ma, Qiang},
title = {Systemic angiogenic protein changes following propranolol therapy in infantile hemangioma: a multi-target perspective},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1706048}
}
EUVIMED